Inactive Instrument

Highlights MannKind Corporation Nasdaq

Equities

US56400P2011

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Mar. 26	MannKind CFO Binder to Retire in April, Names New CFO	MT
Mar. 26	MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MannKind Corporation Announces INHALE-3 Study?s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections and Insulin Pumps	Mar. 11	CI
Earnings Flash (MNKD) MANNKIND Reports Q4 Revenue $58.5M, vs. Street Est of $53.1M	Feb. 27	MT
MannKind Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®	Feb. 15	CI
MannKind Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (MNKD) MANNKIND Reports Q3 Revenue $51.3M, vs. Street Est of $50.7M	Nov. 07	MT
MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 Diabetes	Nov. 06	CI
MannKind Reports Q2 Breakeven, Revenue Rises	23-08-08	MT
MannKind Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Earnings Flash (MNKD) MANNKIND Reports Q2 Revenue $48.6M, vs. Street Est of $42.9M	23-08-07	MT
Earnings Flash (MNKD) MANNKIND Reports Q2 EPS $0.00, vs. Street Est of $-0.04	23-08-07	MT
Mannkind Corporation Launches Inhale-3 Study to Address the Most Important Unmet Need in Adults Living with Type 1 Diabetes	23-06-22	CI
MannKind's Q1 Loss Narrows, Revenue Rises	23-05-10	MT
MannKind Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Earnings Flash (MNKD) MANNKIND Posts Q1 Revenue $41M, vs. Street Est of $37.4M	23-05-09	MT
MannKind's Q4 Loss Narrows, Revenue Rises	23-02-23	MT
MannKind Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
MannKind Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-23	CI
MannKind Corporation Announces its Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease	23-01-23	CI
MannKind Reports Wider Loss, Rising Revenue in Q3; Shares Gain	22-11-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MannKind Corporation Nasdaq

Equities

US56400P2011

Highlights

Filters